Mapp Biopharmaceutical

Large logo of Mapp Biopharmaceutical
Manufacturer

Headquarters

Flag of United States of AmericaUnited States of America

Mapp Biopharmaceutical was established in 2003 by Drs. Kevin Whaley and Larry Zeitlin with the aim of creating new medicines for the prevention and treatment of infectious diseases, with a focus on addressing unmet requirements in global health and biodefense. Over the past decade, the company has been dedicated to developing an Ebola therapy and collaborating with the governments of the United States and Canada in its creation. Upon the transition of these products to clinical evaluation, LeafBio assumes the responsibilities of ownership and commercialization.

Products & Services

Chok1-Af Cell Line